Seasonal influenza virus vaccine high dose - Sanofi Pasteur
Alternative Names: Fluzone HD; Fluzone® High Dose IM; Fluzone® High-Dose influenza vaccine; Seasonal influenza virus vaccine - sanofiLatest Information Update: 08 Apr 2022
At a glance
- Originator sanofi pasteur
- Developer Peter MacCallum Cancer Centre; Sanofi; Sanofi K.K.
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 10 Nov 2021 Phase-II clinical trials in Influenza virus infections (In adolescents, In children, In infants, In neonates), prior to November 2021 (IM) (Sanofi pipeline, November 2021)
- 07 Sep 2020 Sanofi Pasteur plans a phase III trial for Influenza (In infants, In Children) in Australia, Brazil, Chile, Colombia, Czech Republic, Finland, Germany, Italy, Mexico, Philippines, Poland, South Africa, Spain, Taiwan and USA (IM) (EudraCT2019-004721-24)
- 21 Apr 2020 Sanofi completes a phase II/III trial in Influenza virus infections (In adults, Prevention) in Australia (IM) (ACTRN12619000617167)